Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Table 3 Hazard ratio of death, based on patient characteristics and treatments received

Variable	Contrast	HR (95% CI)	P value
Multivariate landmark analysis (n = 642)
Regimen	AT + HER2 vs. A + T	0.90 (0.37–2.20)	0.82
	PC vs. A + T	1.28 (0.55–2.98)	0.56
	A no T vs. A + T	1.25 (0.47–3.35)	0.66
Age	21–40 vs. 41–60	2.00 (1.05–3.82)	0.036
Age	> 60 vs. 41–60	2.04 (1.01–4.15)	0.048
Postmenopausal	Yes vs. no	0.82 (0.43–1.59)	0.57
Stage	IIB vs. IIA	1.15 (0.60–2.23)	0.67
	IIIA vs. IIA	0.73 (0.24–2.15)	0.56
	IIIB vs. IIA	2.06 (0.87–4.88)	0.099
	IIIC vs. IIA	2.26 (1.11–4.61)	0.024
Grade	III vs. I/II	0.67 (0.35–1.28)	0.22
Subtype	HER2-amplified vs. TN	0.56 (0.25–1.28)	0.17
Subtype	HR vs. TN	1.00 (0.46–2.22)	0.99
Adjuvant chemotherapy	Yes vs. no	1.33 (0.64–2.77)	0.45
Adjuvant hormone therapy	Yes vs. no	0.75 (0.39–1.45)	0.40
Adjuvant radiation treatment	Yes vs. no	0.65 (0.34–1.22)	0.18

Abbreviations: A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC Provider choice, HR Hormone receptor, TN Triple-negative breast cancer
Italicized values are statistically significant

ISSN: 1465-542X